SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Mirum Says Atebrioz Reduced Bone Lesion Volume in FOP Trial

Mirum reported reduced bone lesion volume in a trial of Atebrioz in children aged 6 to under 12.

MIRM

Related stories